# US 2004/0082631 A1 · Pyrazole compositions useful as inhibitors of ERK

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082631 A1
- Document ID: US20040082631A1
- Status: Published application
- Kind: A1
- Application number: 10/686,690
- Filed: 2003-10-16
- Published: 2004-04-29
- Earliest claimed: 2000-12-13
- Assignees: Vertex Pharmaceuticals Incorporated
- Inventors: Michael Hale; James Janetka; Francois Maltais
- Web page: https://patentgrep.com/patent/US20040082631A1

## CPC

- C07D 231/38: Nitrogen atoms (nitro radicals C07D231/16)
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1 where R1, R2, T and Ht are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

## Claims

### Claim 1

A compound of formula I:
43
or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
Ht is a heterocyclic ring selected from pyrazol-3-yl, [1,2,4]triazol-3-yl, [1,2,3]triazol-4-yl, or tetrazol-5-yl, said pyrazol-3-yl having R3 and QR4 substituents, and said [1,2,4]triazol-3-yl or [1,2,3]triazol-4-yl substituted by either R3 or QR4;
R1 is selected from R, F, Cl, N(R )2, OR, NRCOR, NRCON(R8)2, CON(R8)2, SO2R, NRSO2R, or SO2N(R8)2;
T is selected from a valence bond or a linker group;
each R is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons;
R2 is selected from hydrogen, CN, halogen, or an optionally substituted group selected from aryl, aralkyl, heteroaryl, heterocyclyl, acyclic aliphatic chain group having one to six carbons, or a cyclic aliphatic group having three to ten carbons;
R3 is selected from R, OH, OR, N(R8)2, F, Cl, or CN;
Q is a valence bond, J, or an optionally substituted C1-6 alkylidene chain wherein up to two nonadjacent carbons of the alkylidene chain are each optionally and independently replaced by J;
J is selected from —C(═O)—, —CO2—, —C(O)C(O)—, —NRCONR8—, —N(R)N(R8)—, —C(═O)NR8—, —NRC(═O)—, —O—, —S—, —SO—, —SO2—, —N(R)O—, —ON(R8)—, —OC(═O)N(R8)—, —N(R)COO—, —SO2N (R8)—, —N(R)SO2—, or —N(R8)—;
R4 is selected from —R8, —R5, —NH2, —NHR5, —N(R5)2, or —NR5 (CH2)yN (R5)2;
each R5 is independently selected from R6, R7, —(CH2)yCH(R6) (R7) , —(CH2)yR6, —(CH2)yCH(R6)2, —(CH2)yCH(R7)2, or —(CH2)yR7;
y is 0-6;
each R6 is an optionally substituted group independently selected from an aliphatic, aryl, aralkyl, aralkoxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, heterocyclyl, heterocyclylalkyl, or heterocyclylalkoxy, group;
each R7 is independently selected from an optionally substituted aliphatic, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, or alkoxycarbonyl;
each R8 is independently selected from R or two R8 on the same nitrogen taken together with the nitrogen optionally form a four to eight membered, saturated or unsaturated heterocyclic ring having one to three heteroatoms;
and each substitutable ring nitrogen is independently substituted by R, NR2, COR, CO2(C1-C6 optionally substituted alkyl), SO2(C1-C6 optionally substituted alkyl), CONR2, or SO2NR2;
provided that: (a) TR2 and QR4 are not the same; (b) TR2 and R3 are not the same; (c) when Ht is tetrazol-5-yl and R1 is methyl, then TR2 is other than hydrogen; (d) when Ht is [1,2,3]triazole-4-yl and R1 and R3 are both methyl, then TR2 is other than hydrogen; and (e) when Ht is pyrazol-3-yl and R1 and R3 are both hydrogen, then TR2 is other than methyl when QR4 is phenyl in the 4-position;.

### Claim 2 (depends on 1)

The compound according to claim 1, said compound is selected from the following:
44
or a pharmaceutically acceptable derivative or prodrug thereof.

### Claim 3 (depends on 2)

The compound according to claim 2 having the formula
45
or a pharmaceutically acceptable derivative or prodrug thereof.

### Claim 4 (depends on 1, 2)

The compound according to any one of claims 1, 2, or 3 having one or more of the following features: (a) Q is —CO—CO2—, or —CONH—; (b) T is a valence bond; (c) R1 is hydrogen or NHR; (d) R2 is an optionally substituted aryl ring; (e) R3 is hydrogen; (f) R4 is selected from R5, —NHR5, —N (R5)2—NR5R6, —NHCHR5R6, or —NHCH2R5; or (g) R5 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl group, (CH2)yR6, (CH2)yR7, or (CH2)yCH (R6) (R7).

### Claim 5 (depends on 4)

The compound according to claim 4 having the formula
46
or a pharmaceutically acceptable derivative or prodrug thereof.

### Claim 6 (depends on 5)

The compound according to claim 5 having the following features: (a) T is a valence bond; (b) R2 is an optionally substituted aryl ring; (c) R4 is selected from R5, —NHR5, —N(R5)2, —NR5R6, —NHCHR5R6, or —NHCH2R5; and (d) R5 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl group, —(CH2)yR6, —(CH2)yR7, or —(CH2)yCH (R6) (R7).

### Claim 7 (depends on 1)

The compound according to claim 1 wherein said compound is selected from those listed in Table 1.

### Claim 8 (depends on 1)

The compound according to claim 1, said compound selected from the following:
47
or a pharmaceutically acceptable derivative or prodrug thereof.

### Claim 9 (depends on 8)

The compound according to claim 8 having one or more of the following features: (a) Q is —CO—, —CO2—, or—CONH—; (b) T is a valence bond; (c) R2 is an optionally substituted aryl ring; (d) R3 is hydrogen; (e) R4 is selected from R5, —NHR5, —N(R5)2, —NR5R6, —NHCHR5R6, or —NHCH2R5; or (f) R5 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl group, (CH2)yR6, (CH2)yR7, or (CH2)yCH(R6) (R7).

### Claim 10 (depends on 9)

The compound according to claim 9 having the formula
48
or a pharmaceutically acceptable derivative or prodrug thereof.

### Claim 11 (depends on 10)

The compound according to claim 10 having the following features: (a) T is a valence bond; (b) R2 is an optionally substituted aryl ring; (c) R4 is selected from R5, —NHR5, —N(R5)2, —NR5R6, —NHCHR5R6, or —NHCH2R5; and (d) R5 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl group, —(CH2)yR6, —(CH2)yR7, or —(CH2)yCH(R6)(R7).

### Claim 12 (depends on 1)

The compound according to claim 1 wherein said compound is selected from those listed in Table 2.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A composition comprising a compound according to any one of claims 1 to 12 in an amount sufficient to detectably inhibit protein kinase activity, said protein kinase selected from one or more of ERK, JAK, JNK, Aurora, GSK, KDR, AKT, or a protein kinase related thereto; and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 13)

The composition according to claim 13 wherein said compound is formulated in a pharmaceutically acceptable manner for administration to a patient.

### Claim 15 (depends on 13)

A composition according to claim 13 further comprising a therapeutic agent, either as part of a multiple dosage form together with said compound or as a separate dosage form.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of inhibiting protein kinase activity in a biological sample, wherein said protein kinase is selected from ERK, JAK, JNK, Aurora, GSK, KDR, AKT, or a protein kinase related thereto, comprising the step of contacting said sample with a compound according to any one of claims 1 to 12.

### Claim 17 (depends on 13)

A method for treating a protein kinase-mediated disease state in a patient, wherein said protein kinase is selected from one or more of ERK, JAK, JNK, Aurora, KDR, AKT, or a protein kinase related thereto, comprising the step of administering to said patient a composition according to claim 13.

### Claim 18 (depends on 17)

The method according to claim 17, comprising the additional step of administering to said patient a therapeutic agent either as part of a multiple dosage form together with said compound or as a separate dosage form.

### Claim 19 (depends on 13)

A method of treating a disease state in a patient, wherein said disease state is selected from cancer, stroke, diabetes, hepatomegaly, cardiovascular disease, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, allergic disorders, inflammation, neurological disorders, a hormone-related disease, conditions associated with organ transplantation, immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, conditions associated with cell death, thrombin-induced platelet aggregation, chronic myelogenous leukemia (CML), liver disease, pathologic immune conditions involving T cell activation, or CNS disorders, comprising the step of administering to said patient a composition according to claim 13.

### Claim 20 (depends on 19)

The method according to claim 19 wherein the disease state is cancer.

### Claim 21 (depends on 20)

The method according to claim 20 wherein the disease state is a cancer selected from breast; ovary; cervix; prostate; testis, genitourinary tract; esophagus; larynx, glioblastoma; neuroblastoma; stomach; skin, keratoacanthoma; lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma; bone; colon, adenoma; pancreas, adenocarcinoma; thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma; seminoma; melanoma; sarcoma; bladder carcinoma; liver carcinoma and biliary passages; kidney carcinoma; myeloid disorders; lymphoid disorders, Hodgkin's, hairy cells; buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx; small intestine; colon-rectum, large intestine, rectum; brain and central nervous system; or leukemia.

### Claim 22 (depends on 20)

The method according to claim 20 comprising the additional step of administering to said patient a chemotherapeutic agent either as part of a multiple dosage form together with said compound or as a separate dosage form.

### Claim 23 (depends on 19)

The method according to claim 19 wherein the disease state is cardiovascular disease.

### Claim 24 (depends on 23)

The method according to claim 23 wherein the disease state is a cardiovascular disease selected from restenosis, cardiomegaly, artherosclerosis, myocardial infarction, or congestive heart failure.

### Claim 25 (depends on 23)

The method according to claim 23 comprising the additional step of administering to said patient a therapeutic agent for treating cardiovascular disease either as part of a multiple dosage form together with said compound or as a separate dosage form.

### Claim 26 (depends on 1)

A composition for coating an implantable device comprising a compound according to claim 1 and a carrier suitable for coating said implantable device.

### Claim 27 (depends on 26)

An implantable device coated with a composition according to claim 26.
